Dapagliflozin 5 mg + Placebo tablet
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Type 2 Diabetes Mellitus
Conditions
Type 2 Diabetes Mellitus
Trial Timeline
Jun 1, 2014 → Nov 1, 2015
NCT ID
NCT02157298About Dapagliflozin 5 mg + Placebo tablet
Dapagliflozin 5 mg + Placebo tablet is a approved stage product being developed by AstraZeneca for Type 2 Diabetes Mellitus. The current trial status is completed. This product is registered under clinical trial identifier NCT02157298. Target conditions include Type 2 Diabetes Mellitus.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02157298 | Approved | Completed |
Competing Products
20 competing products in Type 2 Diabetes Mellitus